Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
91
Recruiting, any sponsor type, condition "steatohepatitis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed487
91 trials
Showing 1 to 25, recently updated first.
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06318169 · 1,350 participants (planned) · Start Mar 13, 2024 · Primary completion Feb 28, 2029
Drug: Pegozafermin · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 375 sites in all
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07527910 · 204 participants (planned) · Start May 22, 2026 · Primary completion Mar 15, 2030
Drug: ALN-PNP; Tirzepatide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sites: Tucson, Arizona; Coronado, California; Pasadena, California · 10 sites in all
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06419374 · 1,800 participants (planned) · Start May 24, 2024 · Primary completion Jun 30, 2028
Drug: Pegozafermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Sites: Birmingham, Alabama; Homewood, Alabama; Chandler, Arizona · 335 sites in all
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07701993 · 1,740 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 23, 2033
Drug: Efimosfermin alfa; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Little Rock, Arkansas; Folsom, California; Montclair, California · 37 sites in all
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHPivotal-lookingRecruiting
Altimmune, Inc.Industry
NCT07795164 · 1,800 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 2028
Drug: Pemvidutide · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sites: Dothan, Alabama; Chandler, Arizona; Tucson, Arizona · 62 sites in all
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07854782 · 1,500 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 3, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD
Sites: Miami, Florida; Marrero, Louisiana; Metairie, Louisiana · 5 sites in all
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07704892 · 380 participants (planned) · Start Jul 22, 2026 · Primary completion Oct 16, 2030
Drug: Efimosfermin alfa; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Little Rock, Arkansas; Arcadia, California; Arroyo Grande, California · 39 sites in all
Madrigal Pharmaceuticals, Inc.Industry
NCT07848191 · 150 participants (planned) · Start Oct 7, 2026 · Primary completion Nov 2027
Drug: Rezdiffra; Resmetirom and 2 more · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; North Little Rock, Arkansas; Coronado, California · 16 sites in all
- SMART Diets for MASLDPivotal-lookingRecruiting
Michigan State UniversityAcademic, hospital or other
NCT07459504 · 102 participants (planned) · Start Nov 5, 2026 · Primary completion Dec 26, 2029
Drug: Essential Amino Acids Supplementation intervention · For: Metabolic-dysfunction Associated Steatotic Liver Disease
Sites: Grand Rapids, Michigan
GlaxoSmithKlineGSK (GSK)
NCT06613698 · 350 participants (planned) · Start Sep 27, 2024 · Primary completion Nov 26, 2027
Drug: GSK4532990; Placebo · For: Liver Diseases, Alcoholic
Sites: Chandler, Arizona; Phoenix, Arizona; Tucson, Arizona · 150 sites in all
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver DiseasePivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481734 · 120 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tesamorelin; Placebo · For: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis
Sites: Shenzhen, China
Boehringer IngelheimBoehringer Ingelheim
NCT07325526 · 30 participants (planned) · Start Feb 27, 2026 · Primary completion Aug 5, 2027
Drug: BI 3802876; Placebo · For: Liver Cirrhosis
Sites: Chandler, Arizona; Coronado, California; La Mesa, California · 28 sites in all
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06528314 · 2,150 participants (planned) · Start Oct 4, 2024 · Primary completion Feb 2030
Drug: Efruxifermin; Placebo · For: NASH - Nonalcoholic Steatohepatitis; MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 359 sites in all
Madrigal Pharmaceuticals, Inc.Industry
NCT07830758 · 90 participants (planned) · Start Oct 16, 2026 · Primary completion Nov 2027
Drug: Resmetirom; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; Heart Failure With Preserved Ejection Fraction (HFPEF)
Sites: Peoria, Arizona; Oxnard, California; Fort Myers, Florida · 5 sites in all
EccogeneIndustry
NCT07288138 · 160 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 15, 2027
Drug: Placebo; ECC4703 and 2 more · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 70 sites in all
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
NCT07391267 · 90 participants (planned) · Start May 25, 2026 · Primary completion Dec 31, 2028
Drug: Semaglutide Oral Tablet · For: Chronic Kidney Diseases; MAFLD
Sites: New Delhi, India
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07631637 · 360 participants (planned) · Start Jul 6, 2026 · Primary completion Jan 29, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis; MASH
Sites: Tucson, Arizona; Pasadena, California; Rialto, California · 24 sites in all
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06215716 · 1,650 participants (planned) · Start Dec 1, 2023 · Primary completion Feb 2033
Drug: Efruxifermin; Placebo · For: NASH With Fibrosis; MASH With Fibrosis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 361 sites in all
- A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASHPivotal-lookingRecruiting
Inipharm Australia Pty LtdIndustry
NCT05945537 · 168 participants (planned) · Start Sep 8, 2023 · Primary completion May 31, 2027
Drug: INI-822 (A) · For: Metabolic Dysfunction-Associated Steatohepatitis
Sites: Camperdown, Australia; Campbelltown, Australia; Newcastle, Australia · 12 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06920043 · 42 participants (planned) · Start Apr 9, 2025 · Primary completion Jul 3, 2028
Drug: Efimosfermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Mesa, Arizona; Tucson, Arizona · 30 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07358546 · 32 participants (planned) · Start Mar 13, 2026 · Primary completion Oct 13, 2027
Drug: Efimosfermin alfa · For: Non-alcoholic Fatty Liver Disease
Sites: Rialto, California; Miami Lakes, Florida; Tampa, Florida · 5 sites in all
- A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07145151 · 156 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 4, 2027
Drug: UBT251; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Sites: Beijing, China
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT03884075 · 104 participants (planned) · Start Jul 24, 2019 · Primary completion Aug 31, 2028
Drug: Semaglutide · For: Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease
Sites: Bethesda, Maryland
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver DiseaseRecruiting
The Cleveland ClinicAcademic, hospital or other
NCT07058155 · 70 participants (planned) · Start Dec 17, 2025 · Primary completion Feb 1, 2029
Drug: Anti-Obesity Pharmacotherapy (Class Effect) · For: Liver Cirrhoses; Portal Hypertension Related to Cirrhosis; Severe Obesity and 1 more
Sites: Cleveland, Ohio
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.